technology

press releases

Date Title and Summary Additional Formats
Toggle Summary Augments $100 million in gross proceeds received in the $250 million January 2018 committed equity financing with Redmile Group, LLC investors; remaining $150 million undrawn capacity terminated BOTHELL, Wash. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an underwritten offering of $250 million aggregate principal amount of 2.50% View HTML
Toggle Summary BOTHELL, Wash. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an underwritten offering of $200 million aggregate principal amount of View HTML
Toggle Summary BOTHELL, Wash. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it has entered into a European patent settlement and global license View HTML
Toggle Summary BOTHELL, Wash. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it has entered into a definitive preferred stock purchase agreement View HTML
Toggle Summary -- Highly statistically significant results with rapid prevention beginning Day One,  50%, 75%, 100% responder rates by month one sustained for three months -- -- 15% of patients had no migraines for a full three months -- -- Conference call and webcast to be held today, January 8 , at 8:30 a.m. View HTML
Toggle Summary BOTHELL, Wash. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its presentation at the upcoming J.P. View HTML
Toggle Summary BOTHELL, Wash. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the 29th Annual Piper Jaffray Healthcare Conference at View HTML
Toggle Summary – PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 – – Eptinezumab Biologics License Application (BLA) submission on track for 2H18 – – Conference call scheduled for 5 p.m. ET today – BOTHELL, Wash. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the 26th Annual Credit Suisse Healthcare Conference at View HTML